AB Corporate Bond Morgan Bond
| EYEG Etf | USD 34.80 0.10 0.29% |
AB Corporate Bond holds a debt-to-equity ratio of 0.029. . AB Corporate's financial risk is the risk to AB Corporate stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
AB Corporate's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. AB Corporate's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the ETF is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps EYEG Etf's retail investors understand whether an upcoming fall or rise in the market will negatively affect AB Corporate's stakeholders.
For most companies, including AB Corporate, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for AB Corporate Bond, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, AB Corporate's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Total Assets 24.3 M |
EYEG |
Given the importance of AB Corporate's capital structure, the first step in the capital decision process is for the management of AB Corporate to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of AB Corporate Bond to issue bonds at a reasonable cost.
| Popular Name | AB Corporate Morgan Stanley 3971 |
| Equity ISIN Code | US49721T1016 |
| Bond Issue ISIN Code | US61744YAL20 |
| S&P Rating | Others |
| Maturity Date | 22nd of July 2038 |
| Issuance Date | 24th of July 2017 |
| Coupon | 3.971 % |
AB Corporate Bond Outstanding Bond Obligations
| Dana 575 percent | US235822AB96 | Details | |
| Volcan Compania Minera | USP98047AC08 | Details | |
| Boeing Co 2196 | US097023DG73 | Details | |
| HSBC Holdings PLC | US404280DR76 | Details | |
| MPLX LP 4125 | US55336VAK61 | Details | |
| MPLX LP 52 | US55336VAL45 | Details | |
| International Game Technology | US460599AD57 | Details | |
| BNP Paribas FRN | USF1R15XK367 | Details | |
| Morgan Stanley 3591 | US61744YAK47 | Details | |
| KIRBY P 42 | US497266AC03 | Details | |
| Morgan Stanley 3971 | US61744YAL20 | Details | |
| Valero Energy Partners | US91914JAA07 | Details | |
| AerCap Global Aviation | US00773HAA59 | Details |
Understaning AB Corporate Use of Financial Leverage
AB Corporate's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures AB Corporate's total debt position, including all outstanding debt obligations, and compares it with AB Corporate's equity. Financial leverage can amplify the potential profits to AB Corporate's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if AB Corporate is unable to cover its debt costs.
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts. Eyegate Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. Please read more on our technical analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out the analysis of AB Corporate Fundamentals Over Time. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
The market value of AB Corporate Bond is measured differently than its book value, which is the value of EYEG that is recorded on the company's balance sheet. Investors also form their own opinion of AB Corporate's value that differs from its market value or its book value, called intrinsic value, which is AB Corporate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AB Corporate's market value can be influenced by many factors that don't directly affect AB Corporate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AB Corporate's value and its price as these two are different measures arrived at by different means. Investors typically determine if AB Corporate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AB Corporate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.